甲状腺功能异常与贫血:前瞻性队列研究与系统综述
在EPIC-Norfolk队列中,12,337名基线有TSH、fT4和Hb的参与者纳入横断面分析,7031名纳入前瞻性分析。亚临床甲状腺功能异常与随访期间Hb变化及贫血风险无关;显性甲状腺功能异常患者的Hb差异无临床相关性。系统综述未发现其他前瞻性研究,横断面和病例对照研究结果可比。
要点
- 亚临床甲减和亚临床甲亢均不是贫血的独立危险因素。
- 显性甲减者调整后Hb较甲功正常者低0.22 g/dL,显性甲亢者低0.08 g/dL。
- 显性甲状腺功能异常者的Hb变化无临床相关性。
核心结论
- 亚临床甲状腺功能异常与随访期间Hb浓度变化无关,且不是发生贫血的独立危险因素。
- 显性甲状腺功能异常患者的Hb浓度差异无临床相关性。
研究设计与样本
- 前瞻性人群队列研究(EPIC-Norfolk队列),横断面分析纳入n=12,337,前瞻性分析纳入n=7,031。
- 系统综述检索MEDLINE和EMBASE(从建库至2017年5月15日)。
主要发现
- 横断面分析中,显性甲减者调整后Hb较甲功正常者低0.22 g/dL(CI 0.07-0.38),显性甲亢者低0.08 g/dL(CI -0.23 to 0.38)。
- 前瞻性分析中,中位随访4.7年,460/7031名参与者发生贫血。
- 亚临床甲减者调整后平均Hb变化为-0.04 g/dL(CI -0.14 to 0.06),亚临床甲亢者为0.05 g/dL(CI -0.10 to 0.20)。
- 亚临床甲减者贫血的调整后风险比HR为0.99(CI 0.67-1.48),亚临床甲亢者为0.52(CI 0.23-1.16)。
- 系统综述未返回其他关于该关联的前瞻性研究,但横断面和病例对照研究显示了可比的结果。
关键数值与推荐
- 甲功正常定义为TSH 0.45-4.49 mIU/L(参照组)。
- 甲减定义为TSH ≥4.50 mIU/L(亚临床甲减为fT4正常,显性甲减为fT4降低)。
- 甲亢定义为TSH ≤0.44 mIU/L(亚临床甲亢为fT4正常,显性甲亢为fT4升高)。
- 贫血定义为女性Hb <12 g/dL,男性Hb <13 g/dL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Even though the association between thyroid dysfunction and anemia is commonly described, it is not known whether it is clinically relevant. This study set out to quantify the association of thyroid dysfunction on hemoglobin (Hb) concentration and risk of anemia. A systematic review (MEDLINE and EMBASE, from inception until May 15, 2017) was conducted to interpret the findings in context. METHODS: Participants from the EPIC-Norfolk cohort with available baseline thyrotropin (TSH), free thyroxine (fT4), and Hb were included. Euthyroidism was defined as TSH 0.45-4.49 mIU/L (reference category), hypothyroidism as TSH ≥4.50 mIU/L (subclinical [SHypo] with normal fT4 or overt [OHypo] with low fT4), and hyperthyroidism as TSH ≤0.44 mIU/L (subclinical [SHyper] with normal fT4 or overt [OHyper] with elevated fT4). Anemia was defined as Hb <12 g/dL in women and Hb <13 g/dL in men. In the cross-sectional analyses, multiple linear regression was used to compare Hb across TSH categories. In the prospective analysis, participants with OHypo/OHyper at baseline were excluded, as it was assumed that they were treated for overt thyroid disease. A covariance model was used to determine change in Hb concentration from baseline to last follow-up, and multivariable Cox regression was used to analyze anemia risk. RESULTS: In the cross-sectional population (n = 12,337), the adjusted Hb was 0.22 g/dL lower [confidence interval (CI) 0.07-0.38] in OHypo compared to euthyroids, and 0.08 g/dL lower [CI -0.23 to 0.38] in OHyper. In the prospective analysis, 460/7031 participants developed anemia over a median follow-up of 4.7 years. The adjusted mean Hb change over time was -0.04 g/dL in SHypo [CI -0.14 to 0.06] and 0.05 g/dL in SHyper [CI -0.10 to 0.20]. The adjusted hazard ratio for anemia was 0.99 [CI 0.67-1.48] in SHypo, and 0.52 [CI 0.23-1.16] in SHyper. The systematic review returned no other prospective studies on this association, but cross-sectional and case-control studies showed comparable results. CONCLUSION: In this first prospective population-based cohort, subclinical thyroid dysfunction was not associated with a change in Hb concentration during follow-up and was not an independent risk factor for developing anemia; variations in Hb concentration in patients with overt thyroid dysfunction were not clinically relevant.
引用
- Floriani C, Feller M, Aubert CE, et al. Thyroid Dysfunction and Anemia: A Prospective Cohort Study and a Systematic Review. Thyroid. 2018. PMID: 29631476. doi:10.1089/thy.2017.0480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。